In this interview, News-Medical had the opportunity to speak with Dr. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor.
Sponsored Content by Rapid Novor IncAug 23 2023Reviewed by Olivia Frost insights from industryDr. Xiabing HanPrincipal Scientist for Antibody DiscoveryRapid Novor The discussion revolved around the significant potential of polyclonal antibody sequencing and other technologies in advancing the field of antibody discovery.
When utilizing in vivo models for antibody discovery, the suitability of animal models poses problems for early development and downstream testing. Immune tolerance, especially if the host expresses the target antigen in its own tissue, can result in challenges with eliciting an effective immune response. Cross-reactivity is particularly important to consider in pre-clinical and safety testing.
What strategies or approaches can be employed to effectively mitigate risks associated with antibody discovery, considering cost and speed? Rigorous target validation is crucial in order to focus resources on the most promising therapeutic areas. Prioritizing well-validated targets with strong biological rationale increases the likelihood of success and reduces the risk of investing into targets with limited therapeutic potential.
By combining these strategies, researchers can streamline and improve the efficiency of antibody discovery campaigns, maximizing the chances of identifying successful therapeutic candidates and setting up early production for success.What impact does AI and machine learning have in antibody discovery? These technologies already play a crucial role in enhancing various aspects of antibody discovery.
Our antibody discovery pipeline begins with creating an immunization protocol tailored to the target host species. REpAb is a species agnostic antibody discovery platform; we have worked with humans, sheep, dogs, alpaca, goats, chickens, and rabbits and have the flexibility to adapt to more. We conclude our REpAb discovery programs by recombinantly expressing the antibody sequences we’ve obtained and subsequently characterizing them. We screen and profile antibody leads with SPR for binding kinetics and HDX-MS for epitope mapping. We may also perform functional assays such as cell-based neutralization assays.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Everton transfer news - Hudson-Odoi interest, Che Adams 'medical'Everton transfer news, rumours, gossip and speculation including the latest on Che Adams, Willy Gnonto and more
Lire la suite »
Nottingham Forest transfer news as Montiel medical due and Chelsea man wantedLatest Nottingham Forest transfer news from NottinghamshireLive
Lire la suite »
- medical research advances and health newsMedical and health news service that features the most comprehensive coverage in the fields of neuroscience, cardiology, cancer, HIV/AIDS, psychology, psychiatry, dentistry, genetics, diseases and conditions, medications and more.
Lire la suite »
Transfer news LIVE: Jeremy Doku undergoes Man City medical, Real Madrid 'prepare late Kylian Mbappe bid'MANCHESTER CITY are closing in on a sensational deal for Jeremy Doku – and the speedy winger is expected to have his medical today. However, City’s deal for Paqueta has collapsed follow…
Lire la suite »